Document Detail


Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.
MedLine Citation:
PMID:  22142685     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cancer-targeting drug delivery can be based on the rational design of a therapeutic platform. This approach is typically achieved by the functionalization of a nanoparticle with two distinct types of molecules, a targeting ligand specific for a cancer cell, and a cytotoxic molecule to kill the cell. The present study aims to evaluate the validity of an alternative simplified approach in the design of cancer-targeting nanotherapeutics: conjugating a single type of molecule with dual activities to nanoparticles, instead of coupling a pair of orthogonal molecules. Herein we investigate whether this strategy can be validated by its application to methotrexate, a dual-acting small molecule that shows cytotoxicity because of its potent inhibitory activity against dihydrofolate reductase and that binds folic acid receptor, a tumor biomarker frequently upregulated on the cancer cell surface. This article describes a series of dendrimer conjugates derived from a generation 5 polyamidoamine (G5 PAMAM) presenting a multivalent array of methotrexate and also demonstrates their dual biological activities by surface plasmon resonance spectroscopy, a cell-free enzyme assay, and cell-based experiments with KB cancer cells.
Authors:
Ming-Hsin Li; Seok Ki Choi; Thommey P Thomas; Ankur Desai; Kyung-Hoon Lee; Alina Kotlyar; Mark M Banaszak Holl; James R Baker
Related Documents :
24142235 - Systemic therapy for colorectal cancer: patterns of chemotherapy and biologic therapy u...
9046645 - Photochemotherapy for mycosis fungoides: current status.
22559975 - Identification of differentially expressed genes in gastric cancer by high density cdna...
19956895 - Adenovirus-mediated cancer gene therapy and virotherapy (review).
19787215 - Vitamin d receptor expression is associated with colon cancer in ulcerative colitis.
16962315 - Multinational clinical trials in oncology and post-trial benefits for host countries: w...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-11-23
Journal Detail:
Title:  European journal of medicinal chemistry     Volume:  47     ISSN:  1768-3254     ISO Abbreviation:  Eur J Med Chem     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-16     Completed Date:  2012-05-29     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  0420510     Medline TA:  Eur J Med Chem     Country:  France    
Other Details:
Languages:  eng     Pagination:  560-72     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
Affiliation:
Michigan Nanotechnology Institute for Medicine and Biological Sciences, and Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / chemistry,  pharmacology
Dendrimers / chemistry*
Folic Acid Antagonists / chemistry,  pharmacology
Humans
KB Cells
Methotrexate / chemistry*,  pharmacology*
Molecular Conformation
Molecular Dynamics Simulation
Nanoconjugates / chemistry*
Surface Plasmon Resonance
Tetrahydrofolate Dehydrogenase / metabolism
Grant Support
ID/Acronym/Agency:
1 R01 CA119409/CA/NCI NIH HHS; R01 CA119409-01/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Dendrimers; 0/Folic Acid Antagonists; 0/Nanoconjugates; 0/PAMAM Starburst; 59-05-2/Methotrexate; EC 1.5.1.3/Tetrahydrofolate Dehydrogenase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Promotion as a clinician educator in academic radiology departments guidelines at three major instit...
Next Document:  Magnoliae Cortex inhibits intimal thickening of carotid artery through modulation of proliferation a...